A3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma
Human malignant pleural mesothelioma (MPM) is a rare, but aggressive tumor of the serosal cavities whose 5-year survival rate is 15%. At present, there are no effective therapies for MPM. Although recent findings suggest that A3 adenosine (A3AR) and P2X7 (P2X7R) receptors can be employed as antitumo...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-10-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.679285/full |
id |
doaj-d91d9ef72ea744a38bbe08ea32028683 |
---|---|
record_format |
Article |
spelling |
doaj-d91d9ef72ea744a38bbe08ea320286832021-10-01T13:07:30ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-10-011110.3389/fonc.2021.679285679285A3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural MesotheliomaFabrizio Vincenzi0John Charles Rotondo1Silvia Pasquini2Francesco Di Virgilio3Katia Varani4Mauro Tognon5Department of Translational Medicine, Pharmacology Section, University of Ferrara, Ferrara, ItalyDepartment of Medical Sciences, Experimental Medicine Section, Laboratories of Cell Biology and Molecular Genetics, University of Ferrara, Ferrara, ItalyDepartment of Translational Medicine, Pharmacology Section, University of Ferrara, Ferrara, ItalyDepartment of Medical Sciences, Experimental Medicine Section, Pathology Unit, University of Ferrara, Ferrara, ItalyDepartment of Translational Medicine, Pharmacology Section, University of Ferrara, Ferrara, ItalyDepartment of Medical Sciences, Experimental Medicine Section, Laboratories of Cell Biology and Molecular Genetics, University of Ferrara, Ferrara, ItalyHuman malignant pleural mesothelioma (MPM) is a rare, but aggressive tumor of the serosal cavities whose 5-year survival rate is 15%. At present, there are no effective therapies for MPM. Although recent findings suggest that A3 adenosine (A3AR) and P2X7 (P2X7R) receptors can be employed as antitumoral pharmacological targets in MPM, their potential role in a combined therapy is currently unknown. The A3AR agonist Cl-IB-MECA and the P2X7 receptor antagonist AZ10606120, as a single compound or in combination, were investigated in vitro for their anti-tumor activities. Assays were carried out in MPM cell lines IST-Mes2 and MPP89 and in primary human normal mesothelial cells (HMCs), as control. Single treatment with Cl-IB-MECA reduced cell proliferation and favored a pro-apoptotic effect in both MPP89 and IST-Mes2 cell lines, whereas AZ10606120 inhibited cell proliferation and induced apoptosis in IST-Mes2, only. The combined treatment with Cl-IB-MECA and AZ10606120 reduced cell proliferation and favored apoptosis in MPP89 and IST-Mes2 cell lines, whereas no synergistic effect was detected. These data cumulatively suggest the absence of a synergistic effect in combined targeting of A3 adenosine and P2X7 receptors of MPM cell lines. This study may stimulate further investigations aimed at determining new combinations of antitumor compounds and more effective therapeutic strategies against MPM.https://www.frontiersin.org/articles/10.3389/fonc.2021.679285/fullmalignant pleural mesotheliomaA3 adenosine receptorP2X7 receptorCl-IB-MECAAZ10606120anticancer therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Fabrizio Vincenzi John Charles Rotondo Silvia Pasquini Francesco Di Virgilio Katia Varani Mauro Tognon |
spellingShingle |
Fabrizio Vincenzi John Charles Rotondo Silvia Pasquini Francesco Di Virgilio Katia Varani Mauro Tognon A3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma Frontiers in Oncology malignant pleural mesothelioma A3 adenosine receptor P2X7 receptor Cl-IB-MECA AZ10606120 anticancer therapy |
author_facet |
Fabrizio Vincenzi John Charles Rotondo Silvia Pasquini Francesco Di Virgilio Katia Varani Mauro Tognon |
author_sort |
Fabrizio Vincenzi |
title |
A3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma |
title_short |
A3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma |
title_full |
A3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma |
title_fullStr |
A3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma |
title_full_unstemmed |
A3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma |
title_sort |
a3 adenosine and p2x7 purinergic receptors as new targets for an innovative pharmacological therapy of malignant pleural mesothelioma |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-10-01 |
description |
Human malignant pleural mesothelioma (MPM) is a rare, but aggressive tumor of the serosal cavities whose 5-year survival rate is 15%. At present, there are no effective therapies for MPM. Although recent findings suggest that A3 adenosine (A3AR) and P2X7 (P2X7R) receptors can be employed as antitumoral pharmacological targets in MPM, their potential role in a combined therapy is currently unknown. The A3AR agonist Cl-IB-MECA and the P2X7 receptor antagonist AZ10606120, as a single compound or in combination, were investigated in vitro for their anti-tumor activities. Assays were carried out in MPM cell lines IST-Mes2 and MPP89 and in primary human normal mesothelial cells (HMCs), as control. Single treatment with Cl-IB-MECA reduced cell proliferation and favored a pro-apoptotic effect in both MPP89 and IST-Mes2 cell lines, whereas AZ10606120 inhibited cell proliferation and induced apoptosis in IST-Mes2, only. The combined treatment with Cl-IB-MECA and AZ10606120 reduced cell proliferation and favored apoptosis in MPP89 and IST-Mes2 cell lines, whereas no synergistic effect was detected. These data cumulatively suggest the absence of a synergistic effect in combined targeting of A3 adenosine and P2X7 receptors of MPM cell lines. This study may stimulate further investigations aimed at determining new combinations of antitumor compounds and more effective therapeutic strategies against MPM. |
topic |
malignant pleural mesothelioma A3 adenosine receptor P2X7 receptor Cl-IB-MECA AZ10606120 anticancer therapy |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.679285/full |
work_keys_str_mv |
AT fabriziovincenzi a3adenosineandp2x7purinergicreceptorsasnewtargetsforaninnovativepharmacologicaltherapyofmalignantpleuralmesothelioma AT johncharlesrotondo a3adenosineandp2x7purinergicreceptorsasnewtargetsforaninnovativepharmacologicaltherapyofmalignantpleuralmesothelioma AT silviapasquini a3adenosineandp2x7purinergicreceptorsasnewtargetsforaninnovativepharmacologicaltherapyofmalignantpleuralmesothelioma AT francescodivirgilio a3adenosineandp2x7purinergicreceptorsasnewtargetsforaninnovativepharmacologicaltherapyofmalignantpleuralmesothelioma AT katiavarani a3adenosineandp2x7purinergicreceptorsasnewtargetsforaninnovativepharmacologicaltherapyofmalignantpleuralmesothelioma AT maurotognon a3adenosineandp2x7purinergicreceptorsasnewtargetsforaninnovativepharmacologicaltherapyofmalignantpleuralmesothelioma |
_version_ |
1716861022614061056 |